Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.
about
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanismMechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphateMurine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptaseStable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnetWhy do HIV-1 and HIV-2 use different pathways to develop AZT resistance?Genetic variation of hepatitis B virus and its significance for pathogenesisComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsRole of Marine Natural Products in the Genesis of Antiviral AgentsStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewHIV-1 reverse transcriptionComputational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 proteaseHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsStructural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceNucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivativesComplexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradationStructural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse TranscriptaseHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanismHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateInvestigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.Interactions between HIV-1 reverse transcriptase and the downstream template strand in stable complexes with primer-templateGlobal Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.Synthesis of guanosine and deoxyguanosine phosphoramidites with cross-linkable thioalkyl tethers for direct incorporation into RNA and DNA.The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsPreparation of DNA and RNA fragments containing guanine N(2)-thioalkyl tethers.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replicationMolecular Basis for Drug Resistance in HIV-1 ProteaseBiochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitorsCross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirPre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
P2860
Q21135752-D3DB181B-B4AA-4AE4-93CB-AF415D773217Q24530586-335EC4DF-F7D7-4D53-9AEE-FB5742ABF6A7Q24647519-1A0FA22F-1A0B-4E78-9B14-1DDB30EC32BEQ24682670-53B58334-349A-4F2F-BB7E-D1C38DCB0C01Q25256872-D9CC7CCA-B676-411B-8450-6A6C9894CE45Q26772348-EDA00C20-6992-44B4-8BB0-926358966803Q26777448-B875B025-C7D1-4B43-9F0C-22A97A59FBFCQ26796360-19E2777F-5C9A-4B89-A3EE-669C24892A4AQ27008867-E64FF188-ED50-4083-A6B9-51E03C5777BCQ27023387-F83736D8-0E06-43E7-8C72-93519EBE428EQ27647665-EF718183-A70F-44E8-B974-ABBA3D00BFE1Q27650325-5DB86A90-AF0C-47D2-954B-EC6B9CF7D4E2Q27657718-F15E1B9F-A9AB-403D-B3B5-F6C58FD6C074Q27660045-F0076E9E-8296-42E5-B6DD-078FD5B3E947Q27675888-CA020E5B-2D58-455D-BD0C-7C2FAAF4BAD9Q27676777-652B9780-B796-4116-8D17-5CF816936317Q27676835-CEA24A19-567B-4E84-BEBE-CEE438D0D5C5Q28250395-C0448539-6386-4A3C-886E-364A884A5711Q30456752-0B5B734A-E4AD-4907-8552-F50579DBD1D3Q33381540-A397C82F-E1E7-411D-A678-DB059744FDCCQ33565179-AFF200A0-3866-4AE1-9F34-C500FEBBB6C2Q33572382-68B6DAED-17B7-4761-95CA-952F3081539EQ33692923-F5E7D64A-317A-4CAB-9FC8-D82E3B291B0EQ33782538-47C1AC8D-ECC5-4B72-B2C6-23F12CCC22CCQ33889635-DEA4D93A-AAED-4307-8DAB-6477B19AAC72Q34092798-DA26DECB-CA6F-4908-927A-8410D414D6F7Q34107343-82E8989F-2012-46C6-80C0-EF74FC29902BQ34257298-645F130F-38B2-4846-A8C8-16DB6284FAD5Q34303603-434C8E5D-0279-4B82-95A4-66BDCAC7A346Q34352431-DED5A88A-35B4-426C-9E85-FFDE57317C85Q34464655-A8560514-679C-44B2-8432-236F1DD2A93CQ34483566-BC4263D9-8DC0-4EDB-8DE2-D7933E15A173Q34933164-DEC7533C-871B-4C30-9E4E-1A645EBA2AB8Q35260370-6D888DF2-9AA3-4014-86A0-5F2DF58FE6DCQ35633587-FFC73750-315F-41DC-9560-D0E58D09BE3BQ35635667-51EF2D30-4EF1-4D5E-A03B-1918A05C4D47Q35857522-7CF9DBB4-BD91-4B04-87CA-715073492FC5Q35912746-61F1E812-966E-40EB-9BE1-FB4F994B971BQ35996025-D3C8E4BF-4EDC-4352-A317-9D0C2EDD7164Q36094751-51F4F7C9-EA89-4F42-8D17-E5F37047BB49
P2860
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@en
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@nl
type
label
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@en
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@nl
prefLabel
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@en
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@nl
P2093
P2860
P356
P1476
Structures of HIV-1 RT-DNA com ...... the anti-AIDS drug tenofovir.
@en
P2093
Arthur D Clark
Barbara L Gaffney
Craig S Gibbs
Donald M Jerina
Eddy Arnold
Jianping Ding
Kirsten L White
Lisa K Naeger
Michael D Miller
P2860
P2888
P304
P356
10.1038/NSMB760
P577
2004-04-25T00:00:00Z